• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Current management of limited-stage SCLC and CONVERT trial impact: results of the EORTC Lung Cancer Group survey

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Levy, A
    Hendriks, LEL
    Le, PC
    Falk, Sally
    Besse, B
    Novello, S
    Dingemans, A
    Hasan, B
    Reck, M
    Berghmans, T
    Faivre-Finn, Corinne
    Show allShow less
    Affiliation
    Department of Radiation Oncology, Gustave Roussy, Institut d'Oncologie Thoracique (IOT), INSERM U1030 Molecular Radiotherapy, Universite Paris-Saclay, F-94805, Villejuif, France;
    Issue Date
    2019
    
    Metadata
    Show full item record
    Abstract
    OBJECTIVES: The CONVERT trial showed that twice-daily (BD) concurrent chemoradiotherapy should continue to be considered the standard of care in localised LS-SCLC. A survey was conducted to assess the impact of the CONVERT trial in clinical practice and to identify any relevant research questions for future trials in this setting. METHODS AND MATERIALS: An EORTC Group online survey of LS-SCLC practice was distributed to the EORTC LCG and to members of several European thoracic oncology societies between April and December 2018. RESULTS: 198 responses were analysed. The majority of respondents (88%, n?=?174) were aware of the CONVERT trial. Radiation oncologists comprised 56% of all respondents. Once-daily (OD) radiotherapy is still the most commonly used regimen, however the use of concurrent BD radiotherapy increased after the publication of CONVERT (n?=?59/186, 32% prior to and n?=?78/187, 42% after the publication, p?=?0.053). The main reasons for not implementing BD after the CONVERT publication were logistical issues (n?=?88, 44%), inconvenience for patients (n?=?56, 28%), and the absence of a statistical survival difference between the two arms in CONVERT (n?=?38, 19%). Brain MRI was used by 28% during staging but more than half (60%) of the respondents did not routinely image the brain during follow-up. The main research questions of interest in LS-SCLC were 1) integrating novel targeted therapies-immunotherapies (n?=?160, 81%), 2) PCI (+/- hippocampal sparing) vs. MRI surveillance (n?=?140, 71%) and, 3) biomarker driven trials (n?=?92, 46%). CONCLUSION: Once daily radiotherapy (60-66?Gy in 30-33 fractions) remains the most prescribed radiotherapy fractionation, despite the findings suggested by the CONVERT trial.
    Citation
    Levy A, Hendriks LEL, Le Pechoux C, Falk S, Besse B, Novello S, et al. Current management of limited-stage SCLC and CONVERT trial impact: results of the EORTC Lung Cancer Group survey. Lung Cancer. 2019 Oct;136:145-7.
    Journal
    Lung Cancer
    URI
    http://hdl.handle.net/10541/622185
    DOI
    10.1016/j.lungcan.2019.08.007
    PubMed ID
    31520867
    Additional Links
    https://dx.doi.org/10.1016/j.lungcan.2019.08.007
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.lungcan.2019.08.007
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Protocol for the CONVERT trial-Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status.
    • Authors: Faivre-Finn C, Falk S, Ashcroft L, Bewley M, Lorigan P, Wilson E, Groom N, Snee M, Fournel P, Cardenal F, Bezjak A, Blackhall F
    • Issue date: 2016 Jan 20
    • Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
    • Authors: Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, Bezjak A, Cardenal F, Fournel P, Harden S, Le Pechoux C, McMenemin R, Mohammed N, O'Brien M, Pantarotto J, Surmont V, Van Meerbeeck JP, Woll PJ, Lorigan P, Blackhall F, CONVERT Study Team
    • Issue date: 2017 Aug
    • Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial.
    • Authors: Tay RY, Fernández-Gutiérrez F, Foy V, Burns K, Pierce J, Morris K, Priest L, Tugwood J, Ashcroft L, Lindsay CR, Faivre-Finn C, Dive C, Blackhall F
    • Issue date: 2019 Jul 1
    • Association of Chemoradiotherapy With Outcomes Among Patients With Stage I to II vs Stage III Small Cell Lung Cancer: Secondary Analysis of a Randomized Clinical Trial.
    • Authors: Salem A, Mistry H, Hatton M, Locke I, Monnet I, Blackhall F, Faivre-Finn C
    • Issue date: 2019 Mar 1
    • Prophylactic Cranial Irradiation for Limited-Stage Small-Cell Lung Cancer Patients: Secondary Findings From the Prospective Randomized Phase 3 CONVERT Trial.
    • Authors: Levy A, Le Péchoux C, Mistry H, Martel-Lafay I, Bezjak A, Lerouge D, Padovani L, Taylor P, Faivre-Finn C
    • Issue date: 2019 Feb
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.